| Title |
11q deletion in neuroblastoma: a review of biological and clinical implications
|
|---|---|
| Published in |
Molecular Cancer, June 2017
|
| DOI | 10.1186/s12943-017-0686-8 |
| Pubmed ID | |
| Authors |
Vid Mlakar, Simona Jurkovic Mlakar, Gonzalo Lopez, John M. Maris, Marc Ansari, Fabienne Gumy-Pause |
| Abstract |
Deletion of the long arm of chromosome 11 (11q deletion) is one of the most frequent events that occur during the development of aggressive neuroblastoma. Clinically, 11q deletion is associated with higher disease stage and decreased survival probability. During the last 25 years, extensive efforts have been invested to identify the precise frequency of 11q aberrations in neuroblastoma, the recurrently involved genes, and to understand the molecular mechanisms of 11q deletion, but definitive answers are still unclear. In this review, it is our intent to compile and review the evidence acquired to date on 11q deletion in neuroblastoma. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 116 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 16% |
| Student > Bachelor | 18 | 16% |
| Researcher | 12 | 10% |
| Student > Master | 8 | 7% |
| Student > Postgraduate | 5 | 4% |
| Other | 14 | 12% |
| Unknown | 40 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 33 | 28% |
| Medicine and Dentistry | 17 | 15% |
| Agricultural and Biological Sciences | 10 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Computer Science | 4 | 3% |
| Other | 5 | 4% |
| Unknown | 42 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2019.
All research outputs
#6,857,559
of 22,985,065 outputs
Outputs from Molecular Cancer
#476
of 1,731 outputs
Outputs of similar age
#108,253
of 315,315 outputs
Outputs of similar age from Molecular Cancer
#5
of 35 outputs
Altmetric has tracked 22,985,065 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,731 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,315 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.